Artbio, a radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ARTs), has named ...

US pharma giant Pfizer today announced positive top-line results from its pivotal Phase III CREST trial evaluating sasanlimab ...

US biopharma Vertex Pharmaceuticals has entered an exclusive collaboration and license agreement with China’s Zai Lab for the ...

Chinese metabolic diseases specialist Hangzhou Sciwind Biosciences has announced details of a deal with Verdiva Bio for the ...

USA-based Light Horse Therapeutics has been established as a new small molecule therapeutics developer, with a $62 million ...

Intellia Therapeutics, a US gene editing company developing CRISPR-based therapies, announced late Thursday its strategic ...

Mountainfield Venture Partners and Keymed Biosciences launch Timberlyne Therapeutics with $180 million in series A funding.

The glaucoma market across the seven major markets is forecast to increase at a compound annual growth rate (CAGR) of 2.1% ...

Numab Therapeutics raises $55 million to advance its multi-specific antibody pipeline targeting inflammation and oncology, ...

The FDA approved 50 novel drugs in 2024, including 18 biosimilars, with many targeting rare diseases and offering ...

USA-based Climb Bio said yesterday it has entered into an exclusive license agreement with Beijing Mabworks Biotech for ...

German biotech CatalYm has appointed Scott Clarke as chief executive (CEO), noting that he brings over two decades of ...